Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pathogen DX

Explore full profile

Develops a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets

Scottsdale, United StatesFounded 2015Biotech & Life Sciences
Valuation $25–50M Last recorded · 2019
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Pathogen DX and the history behind them.

About Pathogen DX

PathogenDx, Inc. operates as a biotechnology company, providing DNA-based pathogen testing solutions designed to enhance safety across the agricultural, food, and clinical sectors. Founded in 2014 by Milan Patel, Michael Hogan, and Eric Lachance, the Scottsdale, Arizona-based firm emerged from technology developed by Dr. Hogan at Baylor Medical College and the University of Arizona. Co-founder Milan Patel, with a background in engineering and business, previously held roles at Intel and served as COO/CFO of GMSbiotech, bringing extensive experience in finance, business strategy, and life sciences. This venture was born from the realization that Dr. Hogan's DNA microarray technology had applications far beyond its original scope in clinical diagnostics for organ transplants.

The company's core offering is its proprietary Dynamic Dimensional Detection (D3 Array™) technology, a microarray-based platform for molecular testing. This system is engineered to simultaneously detect and identify up to 100 different pathogens, including bacteria, fungi, and viruses, from a single sample in approximately six hours. The technology's three-dimensional, lattice-like structure facilitates faster and more efficient binding of DNA targets, enabling rapid and sensitive results that can detect single nucleotide changes. This positions the D3 Array™ as an alternative to conventional methods like qPCR, which has limitations in multiplexing, and Next-Generation Sequencing (NGS), which can be slower and more costly.

PathogenDx operates on a razor-blade business model, selling both the consumable testing kits and the associated, non-proprietary laboratory equipment. This strategy allows laboratories to adopt the technology without significant investment in specific branded hardware. The product suite includes tailored assays for different markets, such as DetectX™, QuantX™, and EnviroX™, which are designed for compliance testing, quantification of microbial loads, and environmental monitoring, respectively. The company serves a diverse client base, including cannabis testing labs, food producers, and clinical diagnostic facilities, helping them to ensure product safety, prevent losses from contamination, and meet regulatory standards.

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
Scottsdale, United States
Sector
Biotech & Life Sciences

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • HALLEY Venture Partners

Series A5 investors entered at this stage

  • Altitude Investment Management
  • Salveo Capital
  • CanopyVentures
  • Entourage Effect Capital
  • Entourage Effect Capital (formerly Cresco Capital Partners)
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pathogen DX on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pathogen DX on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.